米卡芬净诱导1型糖尿病患者低血糖:病例报告与文献综述
一例长期控制不佳的29岁西班牙裔女性1型糖尿病患者,因颈部坏死性筋膜炎并纵隔感染接受广泛抗生素和抗真菌治疗。加用米卡芬净后胰岛素需求降至零持续超过48小时,停用并换用另一种抗真菌药后胰岛素需求回升至基线水平。作者假设米卡芬净可能通过抑制SGLT1功能降低1型糖尿病患者胰岛素需求。
要点
- 1型糖尿病合并严重感染时胰岛素需求通常增加,但加用米卡芬净后可能显著下降。
- 本病例中米卡芬净使用期间胰岛素需求降至零持续超过48小时。
- 停用米卡芬净并换用其他抗真菌药后胰岛素需求回升至基线水平。
核心结论
- 米卡芬净可能抑制SGLT1功能,从而降低1型糖尿病患者的胰岛素需求。
研究设计与样本
- 病例报告:一例29岁西班牙裔女性,有长期控制不佳的1型糖尿病史。
- 入院时糖化血红蛋白13.4%(18.8 mM),因颈部坏死性筋膜炎延伸至纵隔接受多次清创手术、广谱抗生素和抗真菌治疗。
主要发现
- 感染加重、持续管饲和多次清创手术期间胰岛素需求逐步增加。
- 加用米卡芬净后胰岛素需求降至零并持续超过48小时。
- 停用米卡芬净并换用另一种抗真菌药后胰岛素需求回升至基线水平。
关键数值与推荐
- 米卡芬净是一种强效1,3-β-D葡聚糖合成酶抑制剂。
- 口服线性1,3-β-D葡聚糖已被记录可通过抑制肠黏膜钠-葡萄糖转运体1(SGLT1)表达显著降低血糖水平。
临床怎么用
- 1型糖尿病患者使用米卡芬净期间应警惕低血糖风险,密切监测血糖和胰岛素需求。
局限性
- 米卡芬净诱导低血糖的机制尚未确立,仅为基于文献的假设。
- 本文为单例病例报告,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with type 1 diabetes mellitus (T1DM) are insulin dependent. Infection increases insulin resistance and subsequently increases insulin needs. We are reporting a case of a patient with T1DM and severe infection who has reduced insulin needs after starting micafungin therapy. PARTICIPANT: A 29-year-old Hispanic woman with known history of long-standing, uncontrolled T1DM presented for evaluation of worsening dysphagia and dyspnea. She was found to have cervical necrotizing fasciitis extending into the mediastinum and required several debridement surgeries along with broad-spectrum antibiotics and antifungal therapy. She had uncontrolled diabetes with a glycosylated hemoglobin of 13.4% (18.8 mM) on admission. Her insulin requirements progressively increased as a result of worsening infection, continuous tube feeds, and multiple debridement surgeries. She was started on micafungin, a potent 1,3-β-D glucan synthase inhibitor, to broaden antimicrobial coverage when her insulin requirement decreased to zero for >48 hours. Right after discontinuation of micafungin and her switch to a different antifungal, insulin requirements increased back to her baseline needs. RESULTS: This is a report of decreased insulin requirements in a patient with T1DM correlating with micafungin administration. The mechanism of micafungin-induced hypoglycemia is not yet established. Oral administration of linear 1,3-β-D glucan has been documented to decrease blood glucose levels significantly by inhibition of expression of sodium-glucose transporter 1 (SGLT1) in intestinal mucosa. CONCLUSION: We hypothesize that micafungin may inhibit SGLT-1 function and decrease insulin requirements in patient with T1DM.
引用
- Morkos M, Nensey NK, Bindal A, et al. Micafungin-Induced Hypoglycemia in a Patient With Type 1 Diabetes: A Case Report and Review of Literature. J Clin Endocrinol Metab. 2019. PMID: 30398618. doi:10.1210/jc.2018-02017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。